163 related articles for article (PubMed ID: 29332537)
1. AZD9291 Increases Sensitivity to Radiation in PC-9-IR Cells by Delaying DNA Damage Repair after Irradiation and Inducing Apoptosis.
Wu S; Zhu L; Tu L; Chen S; Huang H; Zhang J; Ma S; Zhang S
Radiat Res; 2018 Mar; 189(3):283-291. PubMed ID: 29332537
[TBL] [Abstract][Full Text] [Related]
2. Afatinib increases sensitivity to radiation in non-small cell lung cancer cells with acquired EGFR T790M mutation.
Zhang S; Zheng X; Huang H; Wu K; Wang B; Chen X; Ma S
Oncotarget; 2015 Mar; 6(8):5832-45. PubMed ID: 25714021
[TBL] [Abstract][Full Text] [Related]
3. Overcoming acquired resistance of gefitinib in lung cancer cells without T790M by AZD9291 or Twist1 knockdown in vitro and in vivo.
Liu Z; Gao W
Arch Toxicol; 2019 Jun; 93(6):1555-1571. PubMed ID: 30993382
[TBL] [Abstract][Full Text] [Related]
4. AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells.
Ku BM; Bae YH; Koh J; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Invest New Drugs; 2016 Aug; 34(4):407-15. PubMed ID: 27044261
[TBL] [Abstract][Full Text] [Related]
5. AZD9291 promotes autophagy and inhibits PI3K/Akt pathway in NSCLC cancer cells.
Zhang Z; Zhang M; Liu H; Yin W
J Cell Biochem; 2019 Jan; 120(1):756-767. PubMed ID: 30145802
[TBL] [Abstract][Full Text] [Related]
6. Osimertinib (AZD9291) increases radio‑sensitivity in EGFR T790M non‑small cell lung cancer.
Wang N; Wang L; Meng X; Wang J; Zhu L; Liu C; Li S; Zheng L; Yang Z; Xing L; Yu J
Oncol Rep; 2019 Jan; 41(1):77-86. PubMed ID: 30365094
[TBL] [Abstract][Full Text] [Related]
7. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
Shi P; Oh YT; Zhang G; Yao W; Yue P; Li Y; Kanteti R; Riehm J; Salgia R; Owonikoko TK; Ramalingam SS; Chen M; Sun SY
Cancer Lett; 2016 Oct; 380(2):494-504. PubMed ID: 27450722
[TBL] [Abstract][Full Text] [Related]
8. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K
Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670
[TBL] [Abstract][Full Text] [Related]
9. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
Cross DA; Ashton SE; Ghiorghiu S; Eberlein C; Nebhan CA; Spitzler PJ; Orme JP; Finlay MR; Ward RA; Mellor MJ; Hughes G; Rahi A; Jacobs VN; Red Brewer M; Ichihara E; Sun J; Jin H; Ballard P; Al-Kadhimi K; Rowlinson R; Klinowska T; Richmond GH; Cantarini M; Kim DW; Ranson MR; Pao W
Cancer Discov; 2014 Sep; 4(9):1046-61. PubMed ID: 24893891
[TBL] [Abstract][Full Text] [Related]
10. Loss of EGFR confers acquired resistance to AZD9291 in an EGFR-mutant non-small cell lung cancer cell line with an epithelial-mesenchymal transition phenotype.
Xu J; Zhao X; He D; Wang J; Li W; Liu Y; Ma L; Jiang M; Teng Y; Wang Z; Gu M; Wu J; Wang Y; Yue W; Zhang S
J Cancer Res Clin Oncol; 2018 Aug; 144(8):1413-1422. PubMed ID: 29797219
[TBL] [Abstract][Full Text] [Related]
11. Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model.
Ku BM; Choi MK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
PLoS One; 2018; 13(4):e0194730. PubMed ID: 29641535
[TBL] [Abstract][Full Text] [Related]
12. EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients.
Planchard D; Loriot Y; André F; Gobert A; Auger N; Lacroix L; Soria JC
Ann Oncol; 2015 Oct; 26(10):2073-8. PubMed ID: 26269204
[TBL] [Abstract][Full Text] [Related]
13. High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells.
Nanjo S; Ebi H; Arai S; Takeuchi S; Yamada T; Mochizuki S; Okada Y; Nakada M; Murakami T; Yano S
Oncotarget; 2016 Jan; 7(4):3847-56. PubMed ID: 26716903
[TBL] [Abstract][Full Text] [Related]
14. AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients.
Remon J; Planchard D
Future Oncol; 2015 Nov; 11(22):3069-81. PubMed ID: 26450446
[TBL] [Abstract][Full Text] [Related]
15. Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.
Lee JY; Lee YM; Chang GC; Yu SL; Hsieh WY; Chen JJ; Chen HW; Yang PC
PLoS One; 2011; 6(8):e23756. PubMed ID: 21858220
[TBL] [Abstract][Full Text] [Related]
16. EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291.
Thress KS; Brant R; Carr TH; Dearden S; Jenkins S; Brown H; Hammett T; Cantarini M; Barrett JC
Lung Cancer; 2015 Dec; 90(3):509-15. PubMed ID: 26494259
[TBL] [Abstract][Full Text] [Related]
17. DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild-type NSCLC cells to AZD9291.
Li YL; Ding K; Hu X; Wu LW; Zhou DM; Rao MJ; Lin NM; Zhang C
J Cell Mol Med; 2019 Nov; 23(11):7427-7437. PubMed ID: 31454149
[TBL] [Abstract][Full Text] [Related]
18. MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor-mutant lung cancers.
Gu J; Yao W; Shi P; Zhang G; Owonikoko TK; Ramalingam SS; Sun SY
Cancer; 2020 Aug; 126(16):3788-3799. PubMed ID: 32497272
[TBL] [Abstract][Full Text] [Related]
19. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
[TBL] [Abstract][Full Text] [Related]
20. Aspirin sensitizes osimertinib-resistant NSCLC cells in vitro and in vivo via Bim-dependent apoptosis induction.
Han R; Hao S; Lu C; Zhang C; Lin C; Li L; Wang Y; Hu C; He Y
Mol Oncol; 2020 Jun; 14(6):1152-1169. PubMed ID: 32239624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
